Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Thou Hast It Now. . . | Main | Foaming Up Over the Edge »

April 27, 2004

Bulking Up

Email This Entry

Posted by Derek

In the wake of the Sanofi-Aventis merger, there have been comments in the press about how Sanofi's research labs were more productive. Aventis, by contrast, is said to have been relatively stodgy and lacking in results.

It's true that Sanofi has done very well for itself. They've worked in a number of interesting therapeutic areas, and they've taken good advantage of their opportunities. Why they would want to ruin things, disrupting research for years in a quest to turn the company into an elephant, is another question.

But although I haven't had good things to say about Aventis in the past, I have to stick up for them a bit. I've had occasion to look over their patent activity in recent years, and they've been working on some interesting things. They've gone after targets where they would have been first in class, and they've worked on a lot of different ideas. But their compounds just haven't worked out.

How much of that is due to inadequate research, and how much is due to luck? It's impossible to know. Really good companies can have runs of terrible fortune (talk to Merck about what 2003 was like), so it's hard to prove that Aventis's pipeline is weak because they're doing a bad job. Overall, you'd think that they would have more to show for all the time and money, but we can all fill out a whole list of companies that fit that description.

What I think is certain, though, is that being merged won't help Aventis get things to work much better - not for years, if ever. And it sure won't help Sanofi to jump on research ideas any faster. Giant companies aren't too good at that. And if this merger-of-equals thing goes wrong, way too much effort is going to go into turf wars for anything good to happen. You don't have to look far for examples of that, either.

The only thing that will get bigger and better is the sales force, which is how Pfizer's huge growth has been designed. I regard Pfizer as basically a marketing machine, and perhaps FrancoPharma, or whatever this ungainly beast will be called, is hoping to be another one. That'll be sad. You'll have to keep in mind that this is someone from research talking, but I don't think that's a very high target to aim for.

Comments (0) + TrackBacks (0) | Category: Business and Markets


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .